Document is current

Article History

Received: 9 January 2025

Accepted: 9 April 2025

First Online: 17 April 2025

Declarations

:

: Ethical approval to report this study was obtained from ethical review committee II of the University of Heidelberg (2024-888).

: Not applicable.

: F.M.J and I.K. report travel expenses from Vision RT, Inc. F.S. reports travel expenses and honoraria from Elekta AB and Vision RT, Inc. J. F. reports travel expenses and honoraria from Vision RT, Inc.A.S-C reports no competing interests. J. B-H reports AstraZeneca speaker fees and EBAMed SA consulting fees and travel expenses.C.D. reports Varian research grant and travel expenses, AstraZeneca speaker fees and travel expenses, and DGVS speaker fees and travel expenses. F.A.G. reports travel expenses, stocks and honoraria from TME Pharma AG related to this work; research grants and travel expenses from ELEKTA AB; grants, research grants, travel expenses and honoraria from Carl Zeiss Meditec AG; grants, research grants, travel expenses and honoraria from OncoMANGETx, Inc.; travel expenses and research grants from Varian Medical Systems, Inc.; travel expenses and/or honoraria from Bristol- Myers Squibb, Cureteq AG, Roche Pharma AG, MSD Sharp and Dohme GmbH, Siemens Healthineers AG, Varian Medical Systems, and AstraZeneca GmbH; non-financial support from Oncare GmbH and Opasca GmbH and patent US10857388B2 together with Carl Zeiss Meditec AG and patent EP4119191A1.